Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Affinity Asset Advisors, LLC

Q2 2023 · 13F-HR

Affinity Asset Advisors, LLCholdings as filed

Filed 2023-08-14 · accession 0001387131-23-009765

$286.8M
Reported value
71
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
558868105MDGLMADRIGAL PHARMACEUTICALS INC$21.4M7.45%92,500CommonSOLE
15678U128CERE1EURCEREVEL THERAPEUTICS HLDNG I$17.5M6.10%550,000CommonSOLE
G31249108ESTAESTABLISHMENT LABS HLDGS INC$14.5M5.06%211,608CommonSOLE
16961L106CHINOOK THERAPEUTICS INC$12.3M4.30%321,017CommonSOLE
558868105MDGLMADRIGAL PHARMACEUTICALS INC$12.3M4.28%53,100CALLSOLE
881624209TEVATEVA PHARMACEUTICAL INDS LTD$12.0M4.20%1,600,000CommonSOLE
61775R105MORFUSDMORPHIC HLDG INC$11.6M4.04%201,887CommonSOLE
23257D103CBAYUSDCYMABAY THERAPEUTICS INC$11.5M4.01%1,050,118CommonSOLE
09062X103BIIBBIOGEN INC$11.4M3.97%40,000CommonSOLE
50127T109KURAKURA ONCOLOGY INC$9.6M3.36%910,317CommonSOLE
925050106VRNAVERONA PHARMA PLC$9.5M3.30%447,667CommonSOLE
10806XAB8BBIO 2.5 03/15/27BRIDGEBIO PHARMA INC$9.5M3.30%12,000,000CommonSOLE
03940C100ACLXGBXARCELLX INC$7.2M2.49%226,275CommonSOLE
G72800108PRTAPROTHENA CORP PLC$6.8M2.38%100,000CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$6.5M2.25%376,000PUTSOLE
92686J106VKTXVIKING THERAPEUTICS INC$5.7M1.98%350,000PUTSOLE
152309100CNTACENTESSA PHARMACEUTICALS PLC$5.6M1.94%900,723CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$5.4M1.89%650,875CommonSOLE
04351P101ASNDUSDASCENDIS PHARMA A S$5.2M1.80%57,760CommonSOLE
45258J102IMVTIMMUNOVANT INC$4.9M1.72%260,000CommonSOLE
92686J106VKTXVIKING THERAPEUTICS INC$4.9M1.70%300,000CommonSOLE
046353108AZNNASTRAZENECA PLC$4.3M1.50%60,000CommonSOLE
45790W108INOZYME PHARMA INC$4.2M1.46%751,796CommonSOLE
23282W605CYTKCYTOKINETICS INC$4.1M1.42%125,148CommonSOLE
05280R100AUTLAUTOLUS THERAPEUTICS PLC$3.8M1.32%1,589,017CommonSOLE
N44445109IMTXIMMATICS N.V$3.5M1.21%300,000CommonSOLE
29664WAB1ESPR 4 11/15/25ESPERION THERAPEUTICS INC NE$3.4M1.20%6,925,000CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$3.4M1.19%130,000CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$3.3M1.15%100,696CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$3.1M1.08%130,400CALLSOLE
75615P103REATA PHARMACEUTICALS INC$3.0M1.03%29,105CommonSOLE
15117B202CLDXCELLDEX THERAPEUTICS INC NEW$3.0M1.03%87,031CommonSOLE
31572Q808FGENEURFIBROGEN INC$2.7M0.93%983,300CommonSOLE
31572Q808FGENEURFIBROGEN INC$2.7M0.93%983,300PUTSOLE
98420N105XENEXENON PHARMACEUTICALS INC$2.3M0.81%60,376CommonSOLE
88369M101THESEUS PHARMACEUTICALS INC$2.2M0.78%240,244CommonSOLE
00773J103AEGLEA BIOTHERAPEUTICS INC$2.2M0.77%4,900,000CommonSOLE
92731L106VINCERX PHARMA INC$1.9M0.68%1,492,771CommonSOLE
53000N108LIANYLIANBIO$1.8M0.64%800,676CommonSOLE
12674W109CABACABALETTA BIO INC$1.6M0.56%125,000CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$1.6M0.56%178,292CommonSOLE
46122TAA0PRECIGEN INC$1.5M0.53%1,500,000CommonSOLE
H0036K147ADCTADC THERAPEUTICS SA$1.3M0.45%600,000CommonSOLE
00032Q104WHWKAADI BIOSCIENCE INC$1.3M0.45%187,675CommonSOLE
01438T106ALDXALDEYRA THERAPEUTICS INC$1.3M0.44%150,000CommonSOLE
02083G100NVLSEURALPINE IMMUNE SCIENCES INC$1.2M0.43%118,891CommonSOLE
N62509109NAMSNEWAMSTERDAM PHARMA COMPANY$1.2M0.41%100,000CommonSOLE
03890D108VSAREURARAVIVE INC$1.1M0.38%861,200PUTSOLE
N44821101IFRXINFLARX NV$1.1M0.37%240,200CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$1.1M0.37%62,500CommonSOLE
67080M103NRIXNURIX THERAPEUTICS INC$999,0000.35%100,000CommonSOLE
09077B104BCABGBPBIOATLA INC$975,0000.34%325,000CommonSOLE
31572Q808FGENEURFIBROGEN INC$918,0000.32%340,000CALLSOLE
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$911,0000.32%10,000CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC$898,2500.31%12,500CommonSOLE
59935V107MISTMILESTONE PHARMACEUTICALS IN$855,1940.30%300,068CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$776,1000.27%30,000CommonSOLE
74587V107PBYIPUMA BIOTECHNOLOGY INC$714,2920.25%202,349CommonSOLE
92243G108PCVXVAXCYTE INC$695,3150.24%13,923CommonSOLE
471871103JASPER THERAPEUTICS INC$653,4190.23%476,948CommonSOLE
N44445117IMTXWIMMATICS N.V$632,7500.22%187,204CommonSOLE
87410C104TALARIS THERAPEUTICS INC$608,0000.21%200,000CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$604,2880.21%35,133CommonSOLE
92764N102VIRVIR BIOTECHNOLOGY INC$490,6000.17%20,000CommonSOLE
78462F103SPYSPDR S&P 500 ETF TR$488,2560.17%18,087CommonSOLE
67080N101NUVBNUVATION BIO INC$450,0000.16%250,000CommonSOLE
H57830103NLS PHARMACEUTICS LTD$440,0000.15%400,000CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$428,1180.15%267,574CommonSOLE
N62509117NAMSWNEWAMSTERDAM PHARMA COMPANY$77,3300.03%37,000CommonSOLE
03890D108VSAREURARAVIVE INC$42,3360.01%33,600CALLSOLE
77313F114RCKTWROCKET PHARMACEUTICALS INC$13,9130.00%75,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.